References
- Stark GL, Wood KM, Jack F, on behalf of the Northern Region Lymphoma Group, et al. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432–440.
- Engert A, Ballova V, Haverkamp H, German Hodgkin's Study Group, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052–5060.
- Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–695.
- Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005–6015.
- Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31(12):1522–1529.
- Ezdinli EZ, Stutzman L. Vinblastine VS. nitrogen mustard therapy of Hodgkin’s disease. Cancer. 1968;22(2):473–479.
- Little R, Wittes RE, Longo DL, et al. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998;16(2):584–588.
- Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–1439.
- Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
- Tanaka H, Matsushima H, Nishibu A, et al. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69(17):6987–6994.